Takefumi Komiya is an Oncology physician. OpenAlex indexes 163 publications with 2,999 citations (h-index 28).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
11050 Parkview Circle Dr
Fort Wayne, IN 46845
Telephone
833-724-8326Provider last certified this registry record 6 Jul 2021.
Industry payments
32 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Caris MPI, Inc.Program year20252 payments
- Daiichi Sankyo Inc.Program year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
43.4%Serotonin-3 Receptor Antagonist28%Ondansetron Hcl100%Part D≥36 patientsCorticosteroid15.3%Prednisone100%Part D≥12 patientsNervous system
32.8%Phenothiazine18.5%Prochlorperazine Maleate100%Part D≥26 patientsOpioid Agonist8.5%Oxycodone Hcl100%Part D<11 patients+ 1 more class in this area
Hormonal (systemic)
10.1%l-Thyroxine10.1%Levothyroxine Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Exclusion of Patients with Autoimmune Disease in Lung Cancer Clinical Trials
Asian Pacific Journal of Cancer Prevention
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”